MOSCOW, October 4, 2017 /PRNewswire/ --
Hepatera LLC and its development partner MYR GmbH today announced the completion of the 24 weeks active treatment phase in MYR 202 clinical trial, a Phase 2b study investigating Myrcudex B in chronic hepatitis delta infection. 120 subjects have been enrolled into this study in 20 centers in Russia and Germany. The interim data will be presented at the AASLD conference (The Liver Meeting®) in Washington, DC:
Wedemeyer et al., "Interim results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection"; Publication #37, Oral presentation; Parallel Session 5: Hepatitis B: New Therapies, on October 22nd 2017, 10am-10.15am
"The presentation of this interesting data will certainly be very important for the field," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR`s Clinical Advisory Board.
"We hope that the presentation of our results at the one of the largest hepatology gatherings shall further increase attention to the unmet medical need existing in chronic HDV infection," said Alexander Alexandrov, Chief Medical Officer of MYR GmbH. "We are working enthusiastically on our goal to make Myrcludex В available to these patients who urgently need new therapeutic options as soon as possible."
About Myrcludex B
Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. Myrcludex B has shown good safety profile and anti-viral activity in animal models and in proof-of-concept clinical trials, has received Orphan Designation for treatment of HDV infection from EMA and FDA, and PRIME scheme eligibility from EMA.
"Hepatera" is a private biotech company. The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. The company's first product, Myrcludex B, is aimed at the treatment of chronic hepatitis B and D. Myrcludex B is being developed in the framework of international cooperation with the biotechnology company MYR, GmbH (Germany).
About MYR GmbH
MYR GmbH is a clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections.
About Maxwell Biotech Venture Fund
Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development.
SOURCE MYR GmbH